Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To analyze the literary and own data about clopidogrel influence on platelets during inflammation and to reveal particularities of its usage in ischemic heart disease (IHD) patients with active inflammation. Material and methods. The platelet morphology and a number of leukocyte-platelet aggregates (LTA) were investigated with scanning electron microscopy in 110 patients with stable angina pectoris of I-III functional class and 18 healthy volunteers. Spontaneous and ADP-induced platelet aggregation were assessed with laser aggregatometre manufactured by LLC “BIOLA”. Mean platelet volume (MPV) was estimated with the hematological analyzer . All investigations were performed in IHD patients before and after 2 months of clopidogrel treatment 75 mg a day. Results. IHD patients demonstrated appearance of LTA and big reticular platelets in the blood, increase in MPV and spontaneous aggregation. ADP-induced platelet aggregation was rarely increased probably due to acetylsalicylic acid therapy in all IHD patients. These platelet activity changes are connected with increased risk of thrombotic events and correlated with inflammation markers levels. After 2 months of clopidogrel treatment LTA number reduced in 4 times and big reticular platelets number decreased in 2.5 times as well as MPV and spontaneous aggregation achieved the normal ranges. Conclusion. Clopidogrel has not only antithrombotic effect but also can diminish platelets morphological and functional changes connected with inflammation.

About the Authors

L. I. Buriachkovskaia
Russian Cardiology Research and Production Complex
Russian Federation

A. B. Sumarokov
Russian Cardiology Research and Production Complex
Russian Federation

I. A. Uchitel
Russian Cardiology Research and Production Complex
Russian Federation

E. M. Gupalo
Russian Cardiology Research and Production Complex
Russian Federation


1. Rex S. et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 2009; 102: 97–110

2. Kuznik B.I. Cellular and molecular mechanisms of regulation of the hemostatic system in health and disease. Chita: Ekspress-Izdatel'stvo; 2010. Russian (Кузник Б.И. Клеточные и молекулярные механизмы регуляции системы гемостаза в норме и патологии. Чита: Экспресс-издательство; 2010).

3. Nurden А.Т. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl 1): S13–S33

4. Wang L., Jacobsen S.E., Bengtsson A., Erlinge D. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 2004; 5:16-21

5. Myrtek D., Idzko M. Chemotactic activity of extracellular nucleotides on human immune cells. Purinergic Signal 2007; 3: 5–11

6. Graff J., Harder S., Wahl O. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Ther 2005; 78(5): 468-476

7. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006;55(3): 780-784

8. Solheim S. et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660–664

9. Klinkhardt U. et al. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002; 71: 176–185

10. Klinkhardt U. et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73: 232–241

11. Rao A.K. et al. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006; 96: 738– 743

12. Azar R.R. et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151: 521.e1–521.e4

13. Heitzer T. et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and anti-inflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26: 1648–1652.

14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339

15. Chen Y.G. et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32–36

16. Vavuranakis M. et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther 2006; 28: 860–871

17. Vivekananthan D.P. et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004; 94: 358–360

18. Quinn M.J. et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679–684

19. Saw J. et al. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008; 52: 1826–1833

20. Jeffrey L., Anderson J., 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Circulation 2011; 123: e426-e579

21. Seyfarth H.J. et al. Effect of 300– and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002; 143: 118–123

22. Montalescot G. et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006; 48: 931–938

23. Xiao Z., Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982–1988

24. Wykrzykowska J. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-Selectin and CRP levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis 2009;28:410–17

25. Sambu N. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory bio-markers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart. 2011;97:1661-1667

26. Eisenhardt S., Thiele J., Bannasch H. C-reactive protein How conformational changes influence inflammatory Properties. Cell Cycle 2009; 8(23): 3885-3892

27. Patti G. High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation. J Am Coll Car-diol 2011; 57:771-778

28. Linden M., Jackson D. Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol 2010; 42(11): 1762-1766

29. Michelson A., Barnard M., Krueger L. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104(13): 1533-1537

30. Chu S., Becker R., Berger P. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8(1):148-156

31. Pitchford S.C. Novel uses for anti-platelet agents as anti-inflammatory drugs. British J Pharmacol 2007; 152: 987–1002

32. Muhlestein J. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010; 103: 71–82

33. Approved drug products with therapeutic equivalence evaluations. 31th ed. U.S. Department Of Health And Human Services FDA, 2011. Available at:

34. Yakusevich VV Petrochenko AS, Simonov, VS, etc. The effect on platelet aggregation activity of the original (Plavix, Sanofi-Aventis, France) and generic (Plagril, Dr.Reddy 's, India) drug clopidogrel (results of a randomized comparative crossover study). Clinician 2012; (1): (in press). Russian (Якусевич В.В., Петроченко А.С., Симонов В.С., и др. Влияние на агрегационную активность тромбоцитов оригинального (Плавикс, Sanofi-Aventis, Франция) и генерического (Плагрил, Dr.Reddy’s, Индия) препаратов клопидогреля (результаты рандомизированного сравнительного перекрестного исследования). Клиницист 2012; (1): (в печати)).

For citation:

Buriachkovskaia L.I., Sumarokov A.B., Uchitel I.A., Gupalo E.M. ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS. Rational Pharmacotherapy in Cardiology. 2011;7(6):677-684. (In Russ.)

Views: 481

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)